Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | -0.32% | |
| NR7 | Range Contraction | -0.32% | |
| Wide Bands | Range Expansion | -0.32% | |
| Outside Day | Range Expansion | 0.06% | |
| Wide Bands | Range Expansion | 0.06% | |
| Wide Bands | Range Expansion | 2.94% | |
| Down 3 Days in a Row | Weakness | 2.94% | |
| Down 4 Days in a Row | Weakness | 2.94% | |
| Down 5 Days in a Row | Weakness | 2.94% | |
| Wide Bands | Range Expansion | 1.24% |
| Alert | Time |
|---|---|
| Up 1% | 31 minutes ago |
| Possible NR7 | about 20 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| Up 1% | about 23 hours ago |
| 60 Minute Opening Range Breakout | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 10/31/2024
Agios Pharmaceuticals, Inc. Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Hydrogen Metabolism Organic Chemistry Glutamate Inborn Errors Of Metabolism Pyruvate Kinase Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 62.58 |
| 52 Week Low | 20.96 |
| Average Volume | 629,749 |
| 200-Day Moving Average | 39.96 |
| 50-Day Moving Average | 47.03 |
| 20-Day Moving Average | 51.26 |
| 10-Day Moving Average | 56.33 |
| Average True Range | 2.43 |
| RSI (14) | 60.32 |
| ADX | 26.74 |
| +DI | 35.73 |
| -DI | 22.13 |
| Chandelier Exit (Long, 3 ATRs) | 55.29 |
| Chandelier Exit (Short, 3 ATRs) | 50.54 |
| Upper Bollinger Bands | 62.38 |
| Lower Bollinger Band | 40.13 |
| Percent B (%b) | 0.65 |
| BandWidth | 43.40 |
| MACD Line | 2.79 |
| MACD Signal Line | 2.80 |
| MACD Histogram | -0.0074 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 56.89 | ||||
| Resistance 3 (R3) | 56.86 | 56.08 | 56.51 | ||
| Resistance 2 (R2) | 56.08 | 55.50 | 56.09 | 56.38 | |
| Resistance 1 (R1) | 55.35 | 55.15 | 55.72 | 55.38 | 56.26 |
| Pivot Point | 54.57 | 54.57 | 54.75 | 54.58 | 54.57 |
| Support 1 (S1) | 53.84 | 53.99 | 54.21 | 53.87 | 52.98 |
| Support 2 (S2) | 53.06 | 53.64 | 53.07 | 52.86 | |
| Support 3 (S3) | 52.33 | 53.06 | 52.73 | ||
| Support 4 (S4) | 52.36 |
